Lipid and non-lipid effects of statins

Handbook of Experimental Pharmacology

Volumn 170, Issue , 2005, Pages 365-388

  Paoletti, R ^a   Bolego, C ^a   Cignarella, A ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Coronary heart disease; LDL cholesterol; Plaque stabilization; Pleiotropic effects; Statins

Indexed keywords

EID: 33645756599     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/3-540-27661-0_13     Document Type: Article

References (118)

1. Asztalos BF, Horvath KV, McNamara JR et al. (2002a) Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis 164:361-369
2. Asztalos BF, Horvath KV, McNamara JR et al. (2002b) Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients. J Lipid Res 43:1701-1707
3. Athyros VG, Papageorgiou AA, Mercouris BR et al. (2002) Treatment with atorvastatin to the National Cholesterol Educational Program goal versus usual care in secondary coronary heart disease prevention: the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 18:220-228
4. Avellone G, Di Garbo V, Cordova R et al. (1994) Changes induced by pravastatin treatment on hemostatic and fibrinolytic patterns in patients with type IIB hyperlipoproteinemia. Curr Ther Res 55:1335-1344
5. Aviram M, Rosenblat M, Bisgaier CL, Newton RS (1998) Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 138:271-280
6. Baetta R, Camera M, Comparato C et al. (2002) Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 22:692-698
7. Baldassarre D, Amato M, Bondioli A, Sirtori CR, Tremoli E (2000a) Carotid artery intimamedia thickness measured by ultrasonography in normal clinical practice correlateswell with atherosclerosis risk factors. Stroke 31:2426-2430
8. Baldassarre D, Veglia F, Gobbi C et al. (2000b) Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the Carotid Atherosclerosis Italian Ultrasound Study. Atherosclerosis 151:575-583
9. Balk EM, Lau J, Goudas LC et al. (2003) Effects of statins on nonlipid serum markers associatedwith cardiovascular disease: a systematic review.Ann InternMed 139:670-682
10. BallantyneCM,BlazingMA,HunninghakeDBet al. (2003)Effectonhigh-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS).AmHeart J 146:862-869
11. Bellosta S, Via D, Canavesi M et al. (1998) HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 18:1671-1678
12. Bernini F, Didoni G, Bonfadini G,Bellosta S, FumagalliR(1993)Requirement formevalonate in acetylated LDL induction of cholesterol esterification in macrophages.Atherosclerosis 104:19-26
13. Bolego C,Poli A, Cignarella A,Catapano AL,PaolettiR(2002)Novel statins:pharmacological and clinical results. Cardiovasc Drugs Ther 16:251-257
14. Bonetti PO, Lerman LO, Lerman A (2003) Endothelial dysfunction -a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 23:168-175
15. Camera M, Toschi V, Comparato C et al. (2002) Cholesterol-induced thrombogenicity of the vessel wall: inhibitory effect of fluvastatin. Thromb Haemost 87:748-755
16. Ceriello A, Taboga C, Tonutti L et al. (2002) Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short-and long-term simvastatin treatment. Circulation 106:1211-1218
17. Chang MK, Binder CJ, Torzewski M, Witztum JL (2002) C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA 99:13043-13048
18. Cignarella A, Bolego C, Paoletti R (2003) Impact of statins on novel risk markers. Cardiovasc Drugs Ther 17:361-366
19. Cignarella A, Brennhausen B, von Eckardstein A et al. (1998) Differential effects of lovastatin on the trafficking of endogenous and lipoprotein-derived cholesterol in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol 18:1322-1329
20. Cockerill GW, Huehns TY, Weerasinghe A et al. (2001) Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 103:108-112
21. Colli S, Eligini S, Lalli M et al. (1997) Vastatins inhibit tissue factor in cultured human macrophages -a novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol 17:265-272
22. Colvin PL Jr, Auerbach BJ, Case LD, Hazzard WR, Applebaum-Bowden D (1991) A doseresponse relationship between sex hormone-induced change in hepatic triglyceride lipase and high-density lipoprotein cholesterol in postmenopausal women.Metabolism 40:1052-1056
23. Corsini A, Bellosta S, Baetta R et al. (1999) New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 84:413-428
24. CortellaroM, Cofrancesco E, Arbustini E, et al. (2002) Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study. Thromb Haemost 88:41-47
25. Crouse JR 3rd, Frohlich J, Ose L, Mercuri M, Tobert JA (1999) Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. Am J Cardiol 83:1476-1477
26. Dangas G, Badimon JJ, Smith DA et al. (1999) Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J AmColl Cardiol 33:1294-1304
27. Devaraj S,XuDY, Jialal I (2003) C-reactive protein increases plasminogen activator inhibitor-1 expressionandactivity in humanaortic endothelial cells: implications for themetabolic syndrome and atherothrombosis. Circulation 107:398-404
28. Downs JR, Clearfield M, Weis S et al. (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TexCAPS. JAMA 279:1615-1622
29. Endres M, Laufs U, Huang Z et al. (1998) Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 95:8880-8885
30. Festa A,DAgostino R Jr, Tracy RP,Haffner SM(2002) Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 51:1131-1137
31. Forster LF, Stewart G, Bedford D et al. (2002) Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Atherosclerosis 164:129-145
32. Gertz K, Laufs U, Lindauer U et al. (2003) Withdrawal of statin treatment abrogates stroke protection in mice. Stroke 34:551-557
33. Giroux LM, Davignon J, Naruszewicz M (1993) Simvastatin inhibits the oxidation of lowdensity lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta 1165:335-338
34. Goldbourt U, Yaari S, Medalie JH (1997) Isolated low HDL cholesterol as a risk factor for coronary heart diseasemortality -a 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 17:107-113
35. Gonbert S, Malinsky S, Sposito AC et al. (2002) Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. Atherosclerosis 164:305-311
36. Gordon T, Castelli WP, Hjortland MC, KannelWB, Dawber TR (1977) High density lipoprotein as a protective factor against coronary heart disease -the Framingham Study. Am J Med 62:707-714
37. Gotto AM Jr. (2003) Safety and statin therapy: reconsidering the risks and benefits. Arch Intern Med 163:657-659
38. Guerin M, Egger P, Soudant C et al. (2002) Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis 163:287-296
39. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22
40. Hodis HN, Mack WJ, LaBree L et al. (1998). The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 128:262-269
41. Hussein O, Schlezinger S, Rosenblat M, Keidar S, Aviram M (1997) Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis 128:11-18
42. Jialal I, Stein D, Balis D et al. (2001) Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103:1933-1935
43. John S, Schlaich M, Langenfeld M et al. (1998) Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebocontrolled, double-blind study. Circulation 98:211-216
44. Jones P, Kafonek S, Laurora I, Hunninghake D (1998) Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81:582-587
45. Jones PH, Davidson MH, Stein EA (2003) Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR*Trial). Am J Cardiol 92:152-160
46. Kastelein JJ, Isaacsohn JL, Ose L et al. (2000) Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. AmJ Cardiol 86:221-223
47. Kastelein JJ,Wiegman A, de Groot E (2003) Surrogate markers of atherosclerosis: impact of statins. Atheroscler Suppl 4:31-36
48. KawakamiA,TanakaA,Nakajima K,Shimokado K,YoshidaM(2002) Atorvastatinattenuates remnant lipoprotein-induced monocyte adhesion to vascular endothelium under flow conditions. Circ Res 91:263-271
49. Kempen HJ, Vermeer M, deWit E, Havekes LM (1991) Vastatins inhibit cholesterol ester accumulation in humanmonocyte-derived macrophages. Arterioscler Thromb 11:146-153
50. Kinlay S, Schwartz GG, Olsson AG et al. (2003) High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 108:1560-1566
51. Kleemann R, Princen HM, Emeis JJ et al. (2003) Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation 108:1368-1374
52. Krauss RM (1998) Triglycerides and atherogenic lipoproteins: rationale for lipid management. Am J Med 105:58S-62S
53. Laufs U, Gertz K, Dirnagl U et al. (2002) Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects fromischemic stroke in mice. Brain Res 942:23-30
54. Laufs U, Liao JK (2003) Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep 5:372-378
55. Law MR, Wald NJ, Rudnicka AR (2003) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and metaanalysis. BMJ 326:1423
56. Leung BP, Sattar N, Crilly A et al. (2003) A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 170:1524-1530
57. Liao JK (2002) Isoprenoids as mediators of the biological effects of statins. J. Clin. Invest 110:285-288
58. Libby P, Aikawa M (2003) Mechanisms of plaque stabilization with statins. Am J Cardiol 91:4B-8B
59. Martin G, Duez H, Blanquart C et al. (2001) Statin-induced inhibition of the Rho-signaling pathway activates PPAR? and induces HDL apoA-I. J Clin Invest 107:1423-1432
60. McKenney JM, McCormick LS, Schaefer EJ, Black DM, Watkins ML (2001) Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol 88:270-274
61. Mercuri M, Bond MG, Sirtori CR et al. (1996) Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med 101:627-634
62. Meroni PL, Raschi E,TestoniCet al. (2001) Statinsprevent endothelial cell activationinduced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 44:2870-2878
63. Mullen MJ, Wright D, Donald AE et al. (2000) Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: a double-blind study. J AmColl Cardiol 36:410-416
64. Müller I, Besta F, Schulz C et al. (2003) Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation 108:2195-2197
65. Negre-Aminou P, van Vliet AK, van ErckMet al. (1997) Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta 1345:259-268
66. Nofer JR, Kehrel B, FobkerMet al. (2002) HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 161:1-16
67. OLeary DH, Polak JF, Kronmal RA et al. (1999) Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 340:14-22
68. Olsson AG, Pears J,McKellar J,Mizan J, Raza A (2001) Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 88:504-508
69. Plenge JK, Hernandez TL, Weil KM et al. (2002) Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 106:1447-1452
70. Pontrelli L, Parris W, Adeli K, Cheung RC (2002) Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism 51:334-342
71. Ridker PM (2001) High sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103:1813-1818
72. Ross R (1999) Atherosclerosis: an inflammatory disease. N Engl J Med 340:115-126
73. Rubins HB, Robins SJ, Collins D et al. (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341:410-418
74. Sacks FM (2001) The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials. Am J Cardiol 88:14N-18N
75. Sacks FM for the Expert Group on HDL cholesterol (2002b) The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 90:139-143
76. Sacks FM, Pfeffer MA, Moyé LA et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001-1009
77. Sacks FM, Tonkin AM, Craven T et al. (2002a) Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDLcholesterol and triglycerides as risk factors. Circulation 105:1424-1428
78. Sasaki S, Kuwahara N, Kunitomo K et al. (2002) Effects of atorvastatin on oxidized lowdensity lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia. Am J Cardiol 89:386-389
79. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389
80. Schaefer JR, Schweer H, Ikewaki K et al. (1999)Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis 144:177-184
81. Schartl M, BockschW, Koschyk DH et al. (2001) Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 104:387-392
82. Seljeflot I, Tonstad S, Hjermann I, Arnesen H (2002) Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis 162:179-185
83. Serruys PW, de Feyter P, Macaya C et al. (2002) Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 287:3215-3222
84. Sever PS, Dahlof B, Poulter NR et al. (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patientswho have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial -Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1149-1158
85. Shepherd J, Blauw GJ, Murphy MB et al. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360:1623-1630
86. Shepherd J, Cobbe SM, Ford I et al. (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333:1301-1307
87. Shimizu K, Aikawa M, Takayama K, Libby P, Mitchell RN (2003) Direct anti-inflammatory mechanisms contribute to attenuation of experimental allograft arteriosclerosis by statins. Circulation 108:2113-2120
88. Spieker LE, Sudano I, Hurlimann D et al. (2002) High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105:1399-1402
89. Stein E, Plotkin D, Bays H et al. (2000) Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia. Am J Cardiol 86:406-411
90. Streja L, Packard CJ, Shepherd J, Cobbe S, Ford I (2002) Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in theWest Of Scotland Coronary Prevention Study (WOSCOPS). Am J Cardiol 90:731-736
91. Stuve O, Youssef S, Steinman L, Zamvil SS (2003) Statins as potential therapeutic agents in neuroinflammatory disorders. Curr Opin Neurol 16:393-401
92. Susic D, Varagic J, Ahn J, Slama M, Frohlich ED (2003) Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol 42:1091-1097
93. Suzumura K, Tanaka K, Yasuhara M, Narita H (2000) Inhibitory effects of fluvastatin and its metabolites on hydrogen peroxide-induced oxidative destruction of hemin and lowdensity lipoprotein. Biol Pharm Bull 23:873-878
94. Szmitko PE,Wang CH,WeiselRDet al. (2003)Newmarkers of inflammation and endothelial cell activation -part I. Circulation 108:1917-1923
95. Tan KC, ChowWS, TamSC et al. (2002) Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab 87:563-568
96. Taylor AJ, Kent SM, Flaherty PJ et al. (2002) ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 106:2055-2060
97. TeupserD,Bruegel M, SteinO, SteinY, Thiery J (2001)HMG-CoAreductase inhibitors reduce adhesion of human monocytes to endothelial cells. Biochem Biophys Res Commun 289:838-844
98. The Diabetes Atorvastatin Lipid Intervention (DALI) Study Group (2001) The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia -the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 24:1335-1341
99. The Expert Panel (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment ofHigh Blood Cholesterol in Adults (Adult Treatment Panel III) -Final Report. Circulation 106:3143-3421
100. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349-1357
101. Thompson PD, Clarkson P, Karas RH (2003) Statin-associated myopathy. JAMA 289:1681-1690
102. Tsuruoka H, Khovidhunkit W, Brown BE et al. (2002) Scavenger receptor class B type I is expressed in cultured keratinocytes and epidermis -regulation in response to changes in cholesterol homeostasis and barrier requirements. J Biol Chem 277:2916-2922
103. van de Ree MA, Huisman MV, Princen HMG, Meinders AE, Kluft C (2003) Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin with type 2 diabetes mellitus. Atherosclerosis 166:129-135
104. van Etten RW, de Koning EJP, Honing ML et al. (2002) Intensive lipid lowering by statin therapy does not improve vasoreactivity in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 22:799-804
105. van Venrooij FV, van de Ree MA, Bots ML et al. (2002) Aggressive lipid lowering does not improve endothelial function in type 2 diabetes -the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial. Diabetes Care 25:1211-1216
106. vanWissen S, Smilde TJ, Trip MD et al. (2003) Long term statin treatment reduces lipoprotein( a) concentrations in heterozygous familial hyper cholesterolaemia. Heart 89: 893-896
107. Vaughan CJ, Murphy MB, Buckley BM (1996) Statins do more than just lower cholesterol. Lancet 348:1079-1082
108. von Eckardstein A, Assmann G (2000) Prevention of coronary heart disease by raising high-density lipoprotein cholesterol? Curr Opin Lipidol 11:627-637
109. von Eckardstein A, Huang Y, Assmann G (1994) Physiological role and clinical relevance of high-density lipoprotein subclasses. Curr Opin Lipidol 5:404-416
110. von Eckardstein A, Schulte H, Cullen P, Assmann G (2001) Lipoprotein(a) further increases the risk of coronary events in menwith high global cardiovascular risk. JAmColl Cardiol 37:434-439
111. Wagner AH, Schwabe O, Hecker M (2002) Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ. Br J Pharmacol 136:143-149
112. Walter DH, Rittig K, Bahlmann FH et al. (2002) Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 105:3017-3024
113. Weitz-Schmidt G (2002) Statins as anti-inflammatory agents. Trends Pharmacol Sci 23: 482-486
114. Wierzbicki AS, Mikhailidis DP (2002) Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies. Int J Cardiol 84:53-57
115. Wiklund O, Mattsson-Hultén L, Hurt-Camejo E, Oscarsson J (2002) Effects of simvastatin and atorvastatin on inflammation markers in plasma. J Intern Med 251:338-347
116. Yamamoto A, Arakawa K, Sasaki J et al. (2002) Clinical effects of rosuvastatin, a new HMGCoA reductase inhibitor, in Japanese patients with primary hypercholesterolemia: an early phase II study. J Atheroscler Thromb 9:48-56
117. Young-Xu Y, Chan KA, Liao JK, Ravid S, Blatt CM (2003) Long-term statin use and psychological well-being. J Am Coll Cardiol 42:690-697
118. Youssef F, Seifalian AM, Jagroop IA et al. (2002) The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT). Eur J Vasc Endovasc Surg 23:358-364